Is cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?;Es el cinacalcet un tratamiento coste-efectivo en el hiperparatiroidismo secundario severo en pacientes en hemodiálisis?

Nefrologia

Volumn 28, Issue 5, 2008, Pages 511-516

  Arenas Jiménez, María Dolores ^a   Rebollo, P ^b   Alvarez Ude F ^b   Prieto, L ^b   Gil, M T ^b   Malek, T ^b   Moledous, A ^b   Nunez C ^b  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

^b NONE

Author keywords

Cinacalcet; Cost effectiveness anaylisis; Efficiency; Hyperparathiroidism; Vitamin D

Indexed keywords

CINACALCET; NAPHTHALENE DERIVATIVE;

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PROSPECTIVE STUDIES; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 53049086973     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. USRD 2004 annual data report. Am J Kidney Dis 2005; 45: 8-280.
2. Block GA, Martin KJ, de Francisco AL y cols. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-25.
3. Young EW, Akiba T, Albert JM y cols. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44 (5 Supl. 2): 34-8.
4. Ehrlich JE, Rumberger JA. Detection and clinical management of cardiovascular calcification in ESRD: a review. Dialysis Transplant 2004; 33: 306-313.
5. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22: 2867-78.
6. Arenas MD, Álvarez-Ude F, Gil MT y cols. Application of NKFK/ DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006; 21: 1663-8.
7. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol 2006; 38: 739-43.
8. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 2007; 71: 312-7.
9. Arenas MD, Álvarez-Ude F, Gil MT y cols. Implementation of «K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease» after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22: 1639-44.
10. Hofer AM and Brown EM. Extracelullar calcium sensing and signalling. Nat Rev Cell Biol 2003; 4: 530-8.
11. FDA: Food and Drug Administration [Internet] [Accedida el 7 de mayo de 2008]. Disponible en: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails
12. EMEA: European Medicine Agency [Internet]. c1995-2008 Emea [Accedida el 7 de mayo de 2008]. Disponible en: http://www.emea.europa.eu/humandocs/Humans/ EPAR/mimpara/mimpara.htm
13. Moe SM, Chertow GM, Coburn JW y cols. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-71.
14. Shahapuni I, Mansour J, Harbouche L. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 2005; 18; 226-38.
15. Lindberg JS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int 2005; 67: 760-71.
16. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-800.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Supl. 3): S1-201.
18. Catálogo de Especialidades Farmacéuticas; Consejo General de Colegios Oficiales de Farmacéuticos, 2007.
19. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34-8.
20. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19: 870-6.
21. Arenas MD, Álvarez-Ude F, Torregrosa V, Gil MT, Carretón MA, Moledous A, Núñez C, Devesa R, Albiach B. Consequences of implementation of «K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease» in a population of patients on chronic hemodialysis. J Nephrol 2007; 20: 453-61.
22. Garside R, Pitt M, Anderson R, Mealing S, D'Souza R, Stein K. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in endstage renal disease: a UK perspective. Nephrol Dial Transplant 2007; 11: 1-167.